Pharmafile Logo

chronic diseases

- PMLiVE

Alzheimer’s: the numbers we cannot forget

In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Blue Latitude Health

Sanofi reception

Sanofi launches community health project in China

Partners with local associations to improve chronic disease management

- PMLiVE

How will child public health be prioritised? by Alison Wall

Public health strategist Alison Wall stresses the importance of child public health as a commissioning responsibility.

Say Communications

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

Sanofi reception

Sanofi keeps Toujeo price level with Lantus in UK

French firm hoping to maintain market share with its next-gen insulin product

- PMLiVE

NHS England sets up new £190m hep C fund

Will see patients gain access to treatments from Gilead and AbbVie

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

Sanofi reception

Type 1 diabetes market to double to $13.6bn

New treatments will see this growth by 2023, according to GlobalData

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

England’s Cancer Drugs Fund: Fixing a broken system

Following the culling of 16 medicines from the Fund PME looks at how to improve market access for new oncology products

- PMLiVE

UK must embrace genomics or face medicines “dark age”

Life sciences minister George Freeman calls for NHS to embrace new data and technology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links